目的 探討燈盞細(xì)辛合劑聯(lián)合胞二磷膽堿治療青光眼視神經(jīng)萎縮的臨床療效。方法 選擇2014年8月-2015年8月三峽大學(xué)第一臨床醫(yī)學(xué)院收治的青光眼視神經(jīng)萎縮患者84例,按照治療方法分為對(duì)照組和治療組,每組各42例。對(duì)照組球后注射胞二磷膽堿注射液,2 mL/次,每隔1 d注射1次,20次為1個(gè)療程。治療組在對(duì)照組治療基礎(chǔ)上口服燈盞細(xì)辛合劑,10 mL/次,3次/d,40 d為1個(gè)療程。兩組患者均連續(xù)治療2個(gè)療程。觀察兩組患者的臨床療效,同時(shí)比較兩組視野缺損、P100波潛伏期、視力提高行數(shù)的變化。結(jié)果 治療后,對(duì)照組和治療組總有效率分別為73.81%、90.48%,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。與治療前相比,治療后兩組患者視野缺損、P100潛伏期均顯著減小,同組治療前后差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);但治療組減小的程度更明顯,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組視力的視力提高行數(shù)較對(duì)照組高,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 燈盞細(xì)辛合劑聯(lián)合胞二磷膽堿醫(yī)治青光眼視神經(jīng)萎縮臨床療效顯著,可促進(jìn)患者視力恢復(fù),改善視野缺損,具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Dengzhanxixin Mistura combined with citicoline in treatment of glaucoma optic atrophy. Methods Patients (84 cases) with glaucoma optic atrophy in the First Clinical Medical College of Three Gorges University from August 2014 to August 2015 were enrolled in this study. According to the different treatment plans, patients were divided into treatment group (42 cases) and control group (42 cases). The patients in the control group were iv administered with Citicoline Injection by postocular tissue proper, 2 mL/time, once every other day, and 20 times were as one course of treatment. The patients in the treatment group were po administered with Dengzhanxixin Mistura on the basis of control group, 10 mL/time, three times daily, and 40 d was as one course of treatment. Patients in two groups were treated for two courses. After treatment, the clinical efficacy was evaluated, and the changes of visual field defect, P100 wave incubation period, and the lines number of eyesight improvement in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.81% and 90.48%, respectively, and there were differences between two groups (P < 0.05). Compared with those before treatment, after treatment, visual field defect and P100 wave incubation period in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). The decreased extent in the treatment group was more significantly, and there were differences between two groups (P < 0.05). The line numbers of eyesight improvement in treatment group was better than that of control group, with significant difference between two groups (P < 0.05). Conclusion Dengzhanxixin Mistura combined with citicoline has distinct clinical effect in treatment of glaucoma optic atrophy, and can promote the visual acuity, also can improve visual field defect, which has a certain clinical application value.